Novartis reports positive new heart failure data for Entresto

Novartis has announced the publication of new clinical trial data demonstrating the cardiovascular benefits of its heart failure drug Entresto.

JAMA Cardiology has published results from a post-hoc analysis of data from the PARADIGM-HF trial, demonstrating that treatment with Entresto can significantly improve seven out of ten types of physical and social activities at eight months among heart failure patients with reduced ejection fraction (HFrEF), compared to the current standard of care.

The most significant improvements were seen in the ability to perform household chores and to conduct intimate relationships, with the findings of the analysis based on results from the largest clinical trial ever conducted in heart failure.

Improvements in physical and social activity were equivalent to a difference of nine years of ageing, with these benefits shown to be sustained during the study's three-year follow-up period.

Shreeram Aradhye, chief medical officer and global head of medical affairs at Novartis Pharmaceuticals, said: "These results add to the growing body of evidence that, beyond reducing the risk of death and hospitalisation, Entresto has a positive impact on the quality of life of heart failure patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.